What is NDC 75987-130?

75987-130 is the product NDC for Tepezza (teprotumumab), Teprotumumab 500 mg/1 injection, powder, lyophilized, for solution, listed with the FDA by Horizon Therapeutics USA, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

Horizon Therapeutics USA, Inc., NDC labeler code 75987. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Tepezza?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Tepezza NDC 75987-130 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)75987-130Labeler and product segments. Claims need a package NDC.

Product NDC at billing width75987-0130Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
75987-130-15	75987013015	1 VIAL, SINGLE-DOSE in 1 CARTON (75987-130-15) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSEMarketed from Jan 21, 2020

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Tepezza
Generic name (nonproprietary): teprotumumab
Active ingredients: Teprotumumab — 500 mg/1
Dosage form: Injection, Powder, Lyophilized, For solution
Route: Intravenous
Labeler: Horizon Therapeutics USA, Inc.NDC labeler code 75987
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 761143
Marketing start: Jan 21, 2020
Listing expires: Dec 31, 2027
Other FDA classes: Insulin-like Growth Factor-1 Receptor Inhibitors (Mechanism)
Identifiers: Product ID 75987-130_2fea590d-9312-4134-968c-fa9032d09f76SPL ID 2fea590d-9312-4134-968c-fa9032d09f76SPL set ID 3e6c54a1-cefd-4a5b-a855-ab9f268b6cceRxCUI 2274807, 2274812UNII Y64GQ0KC0A
Pharmacologic class: Insulin-like Growth Factor-1 Receptor Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N475987013015 followed by a unit qualifier and the quantity

Package 75987-0130-15. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 24, 2026.

Indications (excerpt from the label)

TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration. TEPEZZA is an insulin-like growth factor-1 receptor inhibitor indicated for the treatment of Thyroid Eye Disease ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 75987-130

What is NDC 75987-130?: 75987-130 is the product NDC for Tepezza (teprotumumab), Teprotumumab 500 mg/1 injection, powder, lyophilized, for solution, listed with the FDA by Horizon Therapeutics USA, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Tepezza (Teprotumumab).
What is the active ingredient?: Teprotumumab.
Who is the labeler?: Horizon Therapeutics USA, Inc., NDC labeler code 75987. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Tepezza?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Tepezza (Teprotumumab) NDC 75987-130